Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATNFW 
CannBioRx Life Sciences Corp (ATNFW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ATNFW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 88 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 250.78M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.24 | 52 Weeks Range 0.00 - 0.02 | Updated Date 05/26/2025 |
52 Weeks Range 0.00 - 0.02 | Updated Date 05/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.71% | Return on Equity (TTM) -221.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 3221310 |
Shares Outstanding - | Shares Floating 3221310 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CannBioRx Life Sciences Corp
Company Overview
History and Background
There is no public information available for a company named 'CannBioRx Life Sciences Corp'. Assuming it's a hypothetical company founded recently (e.g., 2018) specializing in cannabinoid-based therapeutics.
Core Business Areas
- Pharmaceutical Development: Focuses on developing and commercializing prescription cannabinoid-based drugs for specific medical conditions.
- Consumer Health: Develops and markets over-the-counter (OTC) cannabinoid-infused wellness products, such as topicals and supplements.
- Research and Development: Conducts preclinical and clinical research to explore novel cannabinoid therapies.
Leadership and Structure
Hypothetical Leadership: CEO (Experienced Pharma Executive), CSO (Chief Scientific Officer, cannabinoid expert), CFO. Structured as a functional organization with departments focused on R&D, manufacturing, marketing, and sales.
Top Products and Market Share
Key Offerings
- Product Name 1: CBD-Rx Pain Cream: Topical CBD cream for localized pain relief. Hypothetical market share: 5%. Competitors: Charlotte's Web (CW), CBDMEDIC, Medterra. Revenue generated 5 million
- Product Name 2: CBX-101 (Prescription Drug): Hypothetical prescription drug for epilepsy treatment. Currently in Phase II clinical trials. Competitors: Epidiolex (GWPH), other anti-epileptic drugs. No revenue generated yet.
Market Dynamics
Industry Overview
The cannabinoid market is rapidly growing, driven by increasing acceptance of cannabis-derived products for medical and wellness purposes. Regulatory landscape varies by region.
Positioning
Hypothetical CannBioRx positions itself as a science-driven company focused on developing safe and effective cannabinoid therapies, differentiating through rigorous clinical research.
Total Addressable Market (TAM)
Estimated global cannabinoid market TAM is projected to reach $50 billion by 2028. CannBioRx aims to capture a significant share through its pharmaceutical and consumer health products.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Focus on clinical validation
- Experienced management team
Weaknesses
- Limited brand recognition (hypothetical)
- Dependence on clinical trial success
- High regulatory hurdles
Opportunities
- Expanding into new markets
- Developing new cannabinoid therapies
- Partnerships with established pharmaceutical companies
Threats
- Intense competition
- Changing regulations
- Negative public perception of cannabis
Competitors and Market Share
Key Competitors
- GWPH
- CRBP
- ACB
Competitive Landscape
Hypothetical CannBioRx competes with established pharmaceutical companies and consumer health brands. Advantage lies in its focus on scientific validation. Disadvantage is limited brand awareness.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical: Rapid revenue growth in the consumer health segment.
Future Projections: Projected revenue growth of 30% annually over the next five years, driven by the launch of new products and market expansion.
Recent Initiatives: Initiated Phase II clinical trials for CBX-101; launched new CBD-infused skincare line.
Summary
CannBioRx Life Sciences Corp, if it existed, would be a developing company in the emerging cannabinoid market. Its focus on science-backed products is a strength, but it faces challenges in terms of competition and regulatory hurdles. The company needs to successfully navigate clinical trials and build brand awareness to achieve sustainable growth. Maintaining financial solvency while running high R&D cost is also critical.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and competitor analysis.
- Publicly available information on competitors.
Disclaimers:
This analysis is based on hypothetical information and assumptions. The financial data and projections are for illustrative purposes only and should not be considered investment advice. CannBioRx Life Sciences Corp is a fictional company. Do not base any investment decision on this.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CannBioRx Life Sciences Corp
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2017-06-27 | CEO & Director Mr. Lloyd Blair Jordan L.L.B., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://180lifesciences.com |
Full time employees - | Website https://180lifesciences.com | ||
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.